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in combination with autologous peripheral blood
mononuclear cells via antibody-dependent
cellular cytotoxicity while preventing new
infection
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In order to establish a basis for vaccine development
against human T cell leukemia virus type-I (HTLV-1), we
have evaluated the roles of anti-HTLV-1 neutralizing anti-
bodies using a rat monoclonal antibody (mAb) against
HTLV-1 envelope gp46 (LAT-27) and human polyclonal
IgG purified from sera of HTLV-1-associated myelopathy
(HAM) patients (HAM-IgG). LAT-27 and HAM-IgG
completely blocked the HTLV-1-mediated syncytium for-
mation and T-cell transformation in vitro. Interestingly,
when these antibodies were added to the cultures of CD8+
T cell-depleted peripheral blood mononuclear cells
(PBMCs) from HAM patients, proliferation of Tax-expres-
sing T cells and HTLV-1 p24 production were blocked. In
addition, co-culture of HTLV-1-immortalized T cells with
autologous PBMCs in the presence of LAT-27 or HAM-
IgG, but not F(ab)’2 fragment of LAT-27 or the other
non-neutralizing anti-gp46 mAbs, resulted in eradication
of Tax-expressing cells and the p24 production. A 51Cr
release assay for 24 hours showed a significant killing of
HTLV-1-infected T cells by autologous PBMCs in the pre-
sence of LAT-27 or HAM-IgG, but not F(ab)’2 fragment
of LAT-27, in which depletion of CD16+ cells from the
effector PBMCs significantly reduced the killing activity.
Altogether, the present data demonstrated for the first
time that anti-HTLV-1 gp46 neutralizing antibodies are
capable of not only preventing new infection but also
eliminating HTLV-1-infected cells in the presence of auto-
logous PBMCs mainly via an antibody-dependent cellular
cytotoxicity (ADCC) in vitro. Thus, a vaccine candidate
that can elicit or boost anti-gp46 neutralizing antibody
response may have a potential for prevention and therapy
against HTLV-1 infection.
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